routinely tested pathogens (cytomegalovirus (CMV), dengue virus, HIV-1, human T-lymphotropic virus (HTLV), schistosomiasis, cysticercosis, herpes simplex virus type 1 and 2) were negative.
Cranial magnetic resonance imaging (MRI) showed a diffuse bilateral dural meningeal enhancement with no evidence of leptomeningeal enhancement (Fig 1A and 1B) . Following sagittal T1 fat-suppressed spin-echo contrast-enhanced MRI, leptomeningeal enhancement at the anterior region of the bulb-medullary transition was detected (data not shown). Medical support treatment associated with antiviral and intravenous administration of acyclovir was initiated while the etiological investigation continued. After systemic clinical improvement, nervous system depressant drugs were suspended and a new neurological evaluation was performed. The neurological examination confirmed the existence of asymmetrical severe muscle weakness on both upper and lower limbs, mainly in the distal segment, accompanied by absent deep tendon reflexes, paresthesia in the hands and feet, pain in the back and extremities, and mild sensory abnormalities.
Electromyography revealed demyelinating polyradiculoneuropathy (sensitive and motor) with axonal damage. The exam also indicated signs of severe conduction block in distal segments, most evident on the left side. The electromyography, in addition to the clinical symptoms, was consistent with a diagnosis of acute inflammatory demyelinating polyneuropathy (AIDP), the most prevalent form of Guillain-Barré syndrome (GBS). CSF was collected, and an investigation of dengue, Zika, and chikungunya viral RNA was performed by Real Time quantitative RT-PCR (RT-qPCR) employing virus sequence-specific probes. The results evidenced the presence of Zika and chikungunya viral RNA on CSF. An IgM ELISA test specific for chikungunya virus (EuroImmun, Lübeck, Germany) was also positive in the CSF; however, the results of IgM ELISA for Zika and dengue viruses were both negative on CSF. Additionally, dengue immunoglobulin G (IgG) was positive on serum; however, dengue and Zika IgM were negative on serum. Based on that, definitive laboratory findings supported the diagnosis of an acute chikungunya and Zika virus simultaneous coinfection.
The patient was treated with intravenous human immunoglobulin (IVIG) 0.2g/kg/day for 5 days and evolved with progressive neurological improvement and withdrawal of mechanical ventilation. At 6 months after admission, the patient presents a significant clinical improvement. However, strength deficiency in lower limbs persists, especially on the left side. He now presents urinary retention and needs to use an intermittent catheter for relief. Sensory abnormalities and pain symptoms are no longer a problem, and he's functionally independent.
Discussion
Chikungunya was initially described in 1952 in Tanzania. However, in 2005, the virus reemerged in great outbreaks in the Indian Ocean islands, especially on Reunion Island, where one third of the population was infected [1, 8] . The first important Zika virus outbreak was documented in the Yap Islands in 2007 [9] and a larger outbreak was reported in 2013 in the French Polynesia [4] . In Brazil, the first chikungunya epidemic documented wave occurred in July 2014. Subsequently, Zika virus emerged with a massive outbreak in the first semester of 2015 [10] [11] [12] [13] and a second, much larger wave of chikungunya occurred in 2016. In spite of chikungunya and Zika outbreaks, dengue virus is still the most important arboviral disease in the world. Thus, considering the circulation of all 4 serotypes of dengue virus in Brazil, large dengue outbreaks were common over the last decades. Based on that, the triple epidemic has become a reality, with simultaneous circulation of these 3 viruses [14] (or 7, if you count the 4 different dengue serotypes separately). In this report, we present a severe case of a disease with simultaneous involvement of central and peripheral nervous systems and a discussion about the potential risk of arboviral coinfections to amplify the severity of the disease and to generate atypical clinical presentations.
The clinical presentation of this chikungunya and Zika coinfection case confirmed simultaneous involvement of central and peripheral nervous systems. Although neurologic disturbances associated with several arboviruses were recognized, there is a much higher frequency in neurological impairment following chikungunya and Zika infection than those resulting from dengue virus infection. In fact, chikungunya and Zika can lead to different types of neurological involvement. While the reports associated with chikungunya have a prevalence of central nervous system (CNS) involvement (especially meningitis and encephalitis) [15] , Zika has a higher frequency of peripheral disease, especially GBS [16] . Thus, a concomitant peripheral and CNS disorder becomes a rare opportunity for the study of uncommon arboviral disease manifestations.
Currently, there are only a few reports describing neuroimaging findings of neurological injury associated with chikungunya. Chusri et al. 2011 [17] reported neurological abnormalities in patients with chikungunya infection. In 1 patient, the main brain MRI abnormality was located in the subcortical white matter, with the presence of multiple tiny hyperintense dots in T2-weighted and fluid-attenuated inversion recovery images. On another patient, MRI and electromyography confirmed acute progressive quadriparesis and myeloneuropathy, indicating an acute sensorimotor peripheral neuropathy typical for demyelinating disease. In the case presented in this report, we confirmed chikungunya and Zika infection based on virus RNA detection by RT-qPCR in CSF and chikungunya IgM detection also in the CSF. Acute meningoencephalitis syndrome was diagnosed based on CSF cellular and protein contents, demonstrating the presence of inflammatory cells. In fact, Zika and chikungunya viruses are known to be highly neurotropic, and direct viral replication on the CNS contributes to the neurologic manifestations that are seen during infection. Thus, an inflammatory profile is expected following viral replication on the CNS.
The reports of chikungunya and Zika coinfection are very limited [6, 18, 19] ; this can be explained by the fact that only recently has Zika virus been causing large outbreaks. Thus, the clinical manifestations of Zika and chikungunya coinfections require further investigation. Recently, a case of a pregnant woman with simultaneous detection of dengue, Zika, and chikungunya without any repercussion to the fetus was published. The mother presented the following clinical symptoms: nonpurulent bilateral conjunctivitis; intense upper limbs, thorax, and abdomen pruritic maculopapular rash; headache; mild-to-intense bilateral metacarpophalangeal and wrist arthralgia; and limb edema. Interestingly, no neurological complications were reported in this patient [6] . Moreover, Waggoner et al. reported the identification of 16 cases (4.6%) of Zika and chikungunya coinfections in a group of 263 patients presenting arbovirus symptoms. According to the authors, clinically, the patients with coinfections and monoinfections presented a very similar pattern; the only difference was a slightly higher hospitalization rate in patients with coinfections (83.3%) versus monoinfections (64.0%) [19] . Only recently, in a publication in July 2016, 3 cases of coinfection with neurological complications were notified in Ecuador. Among these 3 coinfections cases, 1 developed GBS [7] . Real Time RT-qPCR laboratory analysis confirmed this case as being positive for Zika and chikungunya based on viral RNA detection in serum and CSF. Additionally to these reports, 7 fatal cases with dengue and chikungunya virus coinfection were reported in Colombia from 2014 to 2015. Although these cases were characterized by variable clinical and laboratory characteristics, only hemorrhagic and no neurological manifestations were documented on these patients [18] . To our knowledge, among neurological complications following chikungunya infection, encephalitis is the most common reported clinical characteristic [15] . Thus, although chikungunya and dengue coinfection cases have been described, most of the studies comparing the clinical significance of coinfections have not demonstrated any type of disease exacerbation or any differential clinical outcome (relative to single infections) [20] [21] [22] . Despite the fact that the patient from the case presented here is 74 years old and survived an acute coinfection, previous reports have shown that age could be considered a risk factor for neurologic complications and mortality for chikungunya infection [23, 24] .
In conclusion, the case presented here points out the need to monitor arboviruses coinfection, especially for 2 important viruses with well-known neurotropism, such as Zika and chikungunya. Since these viruses are now endemic in several countries, we should be aware of more neuro-coinfection cases in the future. Although data on literature is still scarce, we cannot exclude the possibility that coinfections could lead to more severe neurological damage. In fact, the case here presented reinforces the need of arboviruses effective surveillance programs in recently affected areas, especially in those that are now epidemic for Zika. Also, our data alert for a potential risk of more severe diseases as a result of simultaneous infections.
Ethics statement
Ethics approval for the study was obtained from the Oswaldo Cruz Foundation-FIOCRUZ, Aggeu Magalhães Institute, Ethics Committee under the numbers CAE #51106115.8.0000.5190 and PlatBr #1449.432. The individual in this manuscript provided an informed consent to publish these case details.
